chartexchange

Hydreight Highlights U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Technology

PR Newswire | Oct 8, 2026 7:30 AM EDT

Milestone advances the technology behind Hydreight's strategic investment and previously announced U.S. distribution rights VANCOUVER, BC and LAS VEGAS, Oct. 8, 2026 /PRNewswire/ -- Hydreight Technologies Inc. ("Hydreight" or the "Company") (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6) today...

Read original article